SCHEMBL1988095

SCHEMBL1988095

CC(C)(C)OC(=O)N[C@H]1C[C@H](O)C[C@H]1NC(=O)OC(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
BTK Q06187 1/20 0.47
KDM1A O60341 2/20 0.47
NFKB1 P19838 1/20 0.45
NFKB2 Q00653 1/20 0.45
RELA Q04206 1/20 0.45
CHRM2 P08172 1/20 0.44
CHRM1 P11229 1/20 0.44
CHRM3 P20309 1/20 0.44
GAA P10253 2/20 0.42
MAOB P27338 2/20 0.41
MAOA P21397 1/20 0.41
CTSK P43235 2/20 0.41
MEN1 O00255 1/20 0.39
MAPK1 P28482 1/20 0.39
KMT2A Q03164 1/20 0.39
EPHX1 P07099 1/20 0.38
EPHX2 P34913 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18588895 0.91 BTK (0.44) BTKKDM1ANFKB1NFKB2RELA
SCHEMBL12921432 0.90 BTK (0.51) BTKKDM1ANFKB1NFKB2RELA
SCHEMBL25524827 0.90 BTK (0.51) BTKKDM1ANFKB1NFKB2RELA
SCHEMBL12948495 0.90 BTK (0.51) BTKKDM1ANFKB1NFKB2RELA
SCHEMBL15088413 0.90 BTK (0.51) BTKKDM1ANFKB1NFKB2RELA
SCHEMBL15968484 0.90 BTK (0.51) BTKKDM1ANFKB1NFKB2RELA
SCHEMBL3305502 0.89 BTK (0.46) BTKKDM1ANFKB1NFKB2RELA
SCHEMBL7269198 0.89 BTK (0.46) BTKKDM1ANFKB1NFKB2RELA
SCHEMBL12096427 0.89 BTK (0.46) BTKKDM1ANFKB1NFKB2RELA
SCHEMBL4083324 0.89 BTK (0.46) BTKKDM1ANFKB1NFKB2RELA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295171-A1 FUSED HETEROAROMATIC PYRROLIDINONES WELLS THERAPEUTICS, INC. 2023-09-21 US disclosed
US-20230295171-A1 FUSED HETEROAROMATIC PYRROLIDINONES WELLS THERAPEUTICS, INC. 2023-09-21 US disclosed
US-20230295171-A1 FUSED HETEROAROMATIC PYRROLIDINONES WELLS THERAPEUTICS, INC. 2023-09-21 US disclosed
EP-3825316-A1 FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2021-05-26 EP disclosed
EP-3489236-B1 PROCESS FOR THE PREPARATION OF FUSED HETEROAROMATIC PYRROLIDINONES TAKEDA PHARMACEUTICALS CO (JP) 2020-09-30 EP disclosed
EP-3489236-A1 PROCESS FOR THE PREPARATION OF FUSED HETEROAROMATIC PYRROLIDINONES Takeda Pharmaceutical Company Limited (JP) 2019-05-29 EP disclosed
EP-2902392-B1 Fused heteroaromatic pyrrolidinones as syk inhibitors TAKEDA PHARMACEUTICALS CO (JP) 2018-10-17 EP disclosed
US-20180141951-A1 FUSED HETEROAROMATIC PYRROLIDINONES CALITHERA BIOSCIENCES, INC. 2018-05-24 US disclosed
US-20180141951-A1 FUSED HETEROAROMATIC PYRROLIDINONES CALITHERA BIOSCIENCES, INC. 2018-05-24 US disclosed
US-20180141951-A1 FUSED HETEROAROMATIC PYRROLIDINONES CALITHERA BIOSCIENCES, INC. 2018-05-24 US disclosed
US-20130245031-A1 FUSED HETEROAROMATIC PYRROLIDINONES TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) 2013-09-19 US disclosed
US-20130245031-A1 FUSED HETEROAROMATIC PYRROLIDINONES TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) 2013-09-19 US disclosed
US-8440689-B2 Fused heteroaromatic pyrrolidinones TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-14 US disclosed
US-8440689-B2 Fused heteroaromatic pyrrolidinones TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-14 US disclosed
US-8440689-B2 Fused heteroaromatic pyrrolidinones TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-14 US disclosed
US-20130116260-A1 FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-09 US disclosed
US-20130116260-A1 FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-09 US disclosed
US-20130116260-A1 FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-09 US disclosed
US-20110152273-A1 FUSED HETEROAROMATIC PYRROLIDINONES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-23 US disclosed
US-20110152273-A1 FUSED HETEROAROMATIC PYRROLIDINONES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180141951-A1 FUSED HETEROAROMATIC PYRROLIDINONES SYK, ZAP70, LYN BTK 6/4885KDM1A 601/4885NFKB1 233/4885
US-20130116260-A1 FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS SYK, BTK, LYN BTK 2/4885KDM1A 357/4885NFKB1 227/4885
US-20130245031-A1 FUSED HETEROAROMATIC PYRROLIDINONES SYK, ZAP70, LYN BTK 6/4885KDM1A 601/4885NFKB1 233/4885
US-20110152273-A1 FUSED HETEROAROMATIC PYRROLIDINONES SYK, ZAP70, LYN BTK 6/4885KDM1A 601/4885NFKB1 233/4885
US-20230295171-A1 FUSED HETEROAROMATIC PYRROLIDINONES SYK, ZAP70, LYN BTK 6/4885KDM1A 601/4885NFKB1 233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.